Teva Pharmaceutical Industries Ltd reports $17.26 billion revenue for fiscal year ended December 31, 2025, up 4.3%
Teva Pharmaceutical Industries Ltd reported revenue of $17.26 billion for the year ended December 31, 2025, an increase of 4.3% from the previous year ($16.54 billion).
For the same period it posted net income of $1.41 billion, or $1.21 per diluted share (-1.45 a year earlier).
That is a net margin of 8.2%.
On Sanad's AAOIFI Standard 21 screen, Teva Pharmaceutical Industries Ltd is currently not compliant: interest-bearing debt is 34% of market capitalisation (limit 30%), and impure income is 1.2% of revenue (limit 5%).
Is Teva Pharmaceutical Industries Ltd halal?
See the full AAOIFI screening of Teva Pharmaceutical Industries Ltd
See the full AAOIFI screening of Teva Pharmaceutical Industries Ltd
Source: 10-K filed with the U.S. Securities and Exchange Commission on February 3, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.